Sophia K. Heuser,Anthea LoBue,Junjie Li,Zhengbing Zhuge,Francesca Leo,Tatsiana Suvorava,Annika Olsson,Rebekka Schneckmann,Drielle D. Guimaraes Braga,Tanu Srivrastava,Lidia Montero,Oliver J. Schmitz,Joachim P. Schmitt,Maria Grandoch,Eddie Weitzberg,Jon O. Lundberg,John Pernow,Malte Kelm,Mattias Carlström,Miriam M. Cortese-Krott,Anthea LoBue,Junjie Li,Zhengbing Zhuge,Francesca Leo,Tatsiana Suvorava,Annika Olsson,Rebekka Schneckmann,Tanu Srivrastava,Lidia Montero,Maria Grandoch,Eddie Weitzberg,John Pernow,Malte Kelm,Mattias Carlström

Abstract:Arginase 1 (Arg1) is a ubiquitous enzyme belonging to the urea cycle that catalyzes the conversion of l-arginine into l-ornithine and urea. In endothelial cells (ECs), Arg1 was proposed to limit the availability of l-arginine for the endothelial nitric oxide synthase (eNOS) and thereby reduce nitric oxide (NO) production, thus promoting endothelial dysfunction and vascular disease. The role of EC Arg1 under homeostatic conditions is in vivo less understood. The aim of this study was to investigate the role of EC Arg1 on the regulation of eNOS, vascular tone, and endothelial function under normal homeostatic conditions in vivo and ex vivo. By using a tamoxifen-inducible EC-specific gene-targeting approach, we generated EC Arg1 KO mice. Efficiency and specificity of the gene targeting strategy was demonstrated by DNA recombination and loss of Arg1 expression measured after tamoxifen treatment in EC only. In EC Arg1 KO mice we found a significant decrease in Arg1 expression in heart and lung ECs and in the aorta, however, vascular enzymatic activity was preserved likely due to the presence of high levels of Arg1 in smooth muscle cells. Moreover, we found a downregulation of eNOS expression in the aorta, and a fully preserved systemic l-arginine and NO bioavailability, as demonstrated by the levels of l-arginine, l-ornithine, and l-citrulline as well as nitrite, nitrate, and nitroso-species. Lung and liver tissues from EC Arg1 KO mice showed respectively increase or decrease in nitrosyl-heme species, indicating that the lack of endothelial Arg1 affects NO bioavailability in these organs. In addition, EC Arg1 KO mice showed fully preserved acetylcholine-mediated vascular relaxation in both conductance and resistant vessels but increased phenylephrine-induced vasoconstriction. Systolic, diastolic, and mean arterial pressure and cardiac performance in EC Arg1 KO mice were not different from the wild-type littermate controls. In conclusion, under normal homeostatic conditions, lack of EC Arg1 expression is associated with a down-regulation of eNOS expression but a preserved NO bioavailability and vascular endothelial function. These results suggest that a cross-talk exists between Arg1 and eNOS to control NO production in ECs, which depends on both L-Arg availability and EC Arg1-dependent eNOS expression.

Poly (ADP-Ribose) Polymerase 1 Mediated Arginase II Activation Is Responsible for Oxidized LDL-Induced Endothelial Dysfunction.

Poly(ADP‐ribose) Polymerase 1 Deficiency Increases Nitric Oxide Production and Attenuates Aortic Atherogenesis Through Downregulation of Arginase II

Poly(ADP-ribose) Polymerase 1 Inhibition Protects Against Low Shear Stress Induced Inflammation.

Poly(ADP‐ribose)polymerase 1 Inhibition Protects Against Age‐dependent Endothelial Dysfunction

Poly-(ADP-ribose) polymerases inhibition by olaparib attenuates activities of the NLRP3 inflammasome and of NF-κB in THP-1 monocytes

Poly(ADP-ribose) Polymerase Inhibition Prevents Reactive Oxygen Species Induced Inhibition of Aldehyde Dehydrogenase2 Activity

Poly(ADP‐ribose) Polymerase 1 (PARP1) in Atherosclerosis: from Molecular Mechanisms to Therapeutic Implications

Oxidized phospholipids regulate amino acid metabolism through MTHFD2 to facilitate nucleotide release in endothelial cells

ARG2 Impairs Endothelial Autophagy Through Regulation of MTOR and PRKAA/AMPK Signaling in Advanced Atherosclerosis

Angiotensin II Decreases Endothelial Nitric Oxide Synthase Phosphorylation via AT1R Nox/ROS/PP2A Pathway

Arginase I Enhances Atherosclerotic Plaque Stabilization by Inhibiting Inflammation and Promoting Smooth Muscle Cell Proliferation.

PARP-1 (Poly[adp-Ribose] Polymerase 1) Inhibition Protects from Ang II (angiotensin II)–Induced Abdominal Aortic Aneurysm in Mice

Downregulation of eNOS and preserved endothelial function in endothelial-specific arginase 1-deficient mice

Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies

PARP1 Promote Autophagy in Cardiomyocytes Via Modulating FoxO3a Transcription.

Arginase I Attenuates Inflammatory Cytokine Secretion Induced by Lipopolysaccharide in Vascular Smooth Muscle Cells

Ox-Ldl Downregulates Enos Activity Via LOX-1-mediated Endoplasmic Reticulum Stress.

The Poly(adp-Ribosyl)ation of FoxO3 Mediated by PARP1 Participates in Isoproterenol-Induced Cardiac Hypertrophy.

Arginase-II induces vascular smooth muscle cell senescence and apoptosis through p66Shc and p53 independently of its l-arginine ureahydrolase activity: implications for atherosclerotic plaque vulnerability

PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.

Parp1-Mediated Ppar Alpha Poly(Adp-Ribosyl)Ation Suppresses Fatty Acid Oxidation In Non-Alcoholic Fatty Liver Disease